The round builds on Milan-based Wise’s first close, completed in June 2024. That included a venture debt facility from the European Investment Bank (EIB) supported by InvestEU, alongside an equity investment from new investor Wallaby S.p.A, as well as investments from existing partners New Frontier S.r.l., Eureka Venture SGR and Indaco Ventures SGR. ENEA Tech and Biomedical joined the round as a strategic partner.
Wise plans to primarily use the proceeds to advance the development and clinical adoption of its Heron lead for spinal cord stimulation (SCS). The company designed Heron to deliver targeted, directional stimulation through a minimally invasive, percutaneous implant technique.
Heron combines the therapeutic precision of surgical paddle leads with the lower procedural burden of cylindrical leads. The combination translates into higher energy efficiency, better anatomical coverage, improved neural signal sensing and reduced lead migration. Wise says it marks a significant step forward in the treatment of chronic pain.
The company plans to use funds to support Heron’s regulatory pathway and a first-in-human study. It also aims to drive the commercial scale-up of its full electrode portfolio across target markets.
More about the Wise technology and next steps after the funding
Wise develops proprietary “Supersonic Technology” to enable the production of implantable electrodes and brain-computer interface (BCI) systems consisting of stretchable electronic circuits integrated into ultra-thin elastomeric foils.
The company says that, compared to traditional rigid electrodes, its own devices deliver superior tissue conformability, softness and adhesion. These prove critical to both safety and therapeutic efficacy in neuromonitoring and neurostimulation applications.
Wise says its technologies’ unique characteristics also offer enhanced precision in neural signal acquisition and stimulation.
Alongside Heron, the company offers the FDA-cleared Wise Cortical Strip (WCS), a soft, stretchable electrode for intraoperative neurophysiological monitoring (IONM) during brain tumor and epilepsy surgeries. It has commercial availability in Europe, the U.S. and Australia.
With the financing, Wise also added Laura Iris Ferro as its chair and added Giuseppe Corvino to its board of directors. Ferro founded Gentium, a Nasdaq-listed company acquired in 2014 by Jazz Pharmaceuticals. She now serves as president and co-founder of Bio4Dreams.
Commentary from company officials
Luca Ravagnan, CEO of Wise, said:
“The oversubscription of this Series D round is a testament to the strength of what our team has built — in technology, in medical research, and in our relationships with clinicians and partners. Welcoming ENEA Tech and Biomedical into our investor base strengthens our mission to bring genuinely transformative neurotechnology to patients worldwide. With the Heron lead, we are targeting a multi-billion-euro market with a product that addresses a long-lasting unmet clinical need. This financing gives us the resources to complete the journey from bench to bedside.”
Laura Iris Ferro added:
“Wise represents a compelling convergence of advanced materials science, neuroscience, and clinical innovation. Welcoming ENEA Tech and Biomedical on board is a testament to the strength of what WISE has built. I am proud to help the company scale its technology and bring high-impact solutions to patients with neurological conditions and chronic pain.”
